Your browser doesn't support javascript.
loading
Plasma lncRNA FEZF1-AS1 as a potential biomarker for diagnosis of non-small-cell lung carcinoma.
Huang, Yajie; Liu, Guangjie; Ma, Handie; Tian, Yanpeng; Huang, Changjie; Liu, Fang; Jia, Yuxuan; Jiang, Da.
Afiliación
  • Huang Y; Department of Medical Oncology, The Fourth Hospital of Hebei Medical University.
  • Liu G; Undergraduate of Clinical Medicine, Hebei Medical University.
  • Ma H; Department of Thoracic Surgery.
  • Tian Y; Undergraduate of Clinical Medicine, Hebei Medical University.
  • Huang C; Department of Radiotherapy, The Fourth Hospital of Hebei Medical University.
  • Liu F; Department of Obstetrics and Gynecology, the Second Hospital of Hebei Medical University, Shijiazhuang, Hebei.
  • Jia Y; Undergraduate of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong, China.
  • Jiang D; Department of Thoracic Surgery.
Medicine (Baltimore) ; 99(26): e21019, 2020 Jun 26.
Article en En | MEDLINE | ID: mdl-32590821
Diagnosis of numerous cancers has been closely linked to the expression of certain long non-coding RNAs. This study aimed to evaluate levels of plasma FEZ family zinc finger 1 antisense RNA 1 (FEZF1-AS1) relative to non-small-cell lung carcinoma (NSCLC) diagnosis.The level of FEZF1-AS1 in the blood plasma of 126 NSCLC patients and 62 healthy controls was examined by quantitative real-time polymerase chain reaction.Plasma FEZF1-AS1 of the NSCLC group was increased compared with that in the control group (P < .0001). Plasma FEZF1-AS1 could distinguish patients with NSCLC from healthy individuals via the area under the ROC curve (AUC) of 0.855 (95% CI = 0.800-0.909; P = .000). FEZF1-AS1 combined with neuron-specific enolase increased the area under the (ROC) curve to 0.932 (95% CI = 0.897-0.968; P = .018). A high expression level of plasma FEZF1-AS1 was associated with some clinical features of NSCLC. Increased expression of FEZF1-AS1 greatly improved the risk of NSCLC (adjusted OR = 2.42; 95% CI = 1.23-4.76). A significant concentration-dependent relationship was noted between risk of NSCLC and higher FEZF1-AS1 expression (P for trend <.001).Plasma FEZF1-AS1 could potentially be used as a biomarker for NSCLC diagnosis.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Proteínas Represoras / Carcinoma de Pulmón de Células no Pequeñas Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Aged / Female / Humans / Male / Middle aged País/Región como asunto: Asia Idioma: En Revista: Medicine (Baltimore) Año: 2020 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Proteínas Represoras / Carcinoma de Pulmón de Células no Pequeñas Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Aged / Female / Humans / Male / Middle aged País/Región como asunto: Asia Idioma: En Revista: Medicine (Baltimore) Año: 2020 Tipo del documento: Article Pais de publicación: Estados Unidos